Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2008 Dec 20;40(9):447–454. [Article in Spanish] doi: 10.1157/13126421

Influencia de la morbilidad, control metabólico y uso de recursos de los sujetos en situación de riesgo cardiovascular en el ámbito de la atención primaria de salud

Influence of morbidity, metabolic control, and use of resources in subjects with cardiovascular risk in the primary care setting

Antoni Sicras-Mainar a,⁎, Soledad Velasco-Velasco a, Nuria González-Rojas Guix b, Chencho Clemente-Igeño b, José Luis Rodríguez-Cid b
PMCID: PMC7659846  PMID: 19054440

Abstract

Objective

To determine the comorbidity, the therapeutic objectives, and economic impact in subjects with cardiovascular risk in primary care (PC).

Design

Multicentre, cross-sectional study.

Setting

Five urban PC centres, Spain.

Participants

Patients over 55 years seen during the year 2006. Compared according to the presence/absence of a cardiovascular event (CVE).

Measurements

Demographics,cardiovascular/general comorbidity (adjusted clinical groups), Charlson index, clinical parameters,multiple drugs and semi-fixed direct costs (operational) and variables (tests,referrals, drugs). A logistical regression and ANCOVA analysis was performed to correct the models. SPSSWIN Program (P<.05).

Results

Of 24 410 patients, 15.4% (CI,14.9-15.9) had a CVE. The subjects with a CVE showed a higher mortality (4.0% vs 1.8%) and general morbidity (8.1 vs 6.4 episodes) (P<.001). The CVE had an independent association in males (OR=2.7),Charlson index (OR=2.1), dyslipaemia (OR=1.5), depression (OR=1.4), age (OR=1.3), arterial hypertension (OR=1.2)and diabetes (OR=1.1) (P<.005). In primary prevention worse average cholesterols were obtained (211.6 vs 192.4 mg/dL), while in secondary prevention blood glucose was worse (111.3 vs 104.2 mg/dL; P<.001).The average corrected direct costs were €1543.55 versus €1027.65, respectively (P<.001). These differences were maintained in all the cost components.

Conclusions

The presence of a CVE is associated with higher comorbidity, causing an increase in costs. The achievement of therapeutic control objectives could be improved, in primary prevention as well as in secondary. Intervention strategies should be increased to modify life styles in these patients.

Key words: Cardiovascular risk, Comorbidity, Use of resources, Costs, Primary care, Adjusted clinical groups

Bibliografía

  • 1.Casado D. Los efectos del envejecimiento demográfico sobre el gasto sanitario: mitos y realidades. Gac Sanit. 2000;15:154–163. doi: 10.1016/s0213-9111(01)71536-1. [DOI] [PubMed] [Google Scholar]
  • 2.Instituto Nacional de Estadística; Madrid: 2006. Instituto Nacional de Estadística Defunciones según la causa de muerte 2004. [Google Scholar]
  • 3.Tunstall-Pedoe H., Dobson A., Fortmann S., Sans S., Tolonen H. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 2000;355:675–687. doi: 10.1016/s0140-6736(99)11180-2. [DOI] [PubMed] [Google Scholar]
  • 4.Pérez G., Pena A., Sala J., Roset P.N., Masiá R., Marrugat J. and the REGICOR investigators Acute myocardial infarction case fatality,incidence and mortality rates in a population registry in Girona,Spain, 1990-1992. Int J Epidemiol. 1998;27:599–604. doi: 10.1093/ije/27.4.599. [DOI] [PubMed] [Google Scholar]
  • 5.Sans S., Puigdefábregas A., Paluzie G., Monterde A., Balaguer-Vintró I. Increasing trends of acute myocardial infarction in Spain: the MONICA-Catalonia Study. Eur Heart J. 2005:505–515. doi: 10.1093/eurheartj/ehi068. [DOI] [PubMed] [Google Scholar]
  • 6.Plaza I., Villar F., Mata P., Pérez F., Maiquez A., Casanovas J.A. Control de la colesterolemia en España, 2000 Un instrumento para la prevención cardiovascular. Rev Esp Cardiol. 2000;53:815–837. doi: 10.1016/s0300-8932(00)75163-3. [DOI] [PubMed] [Google Scholar]
  • 7.American Heart Association AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 update.AHA Scientific Statement. Circulation. 2002;106:388–391. doi: 10.1161/01.cir.0000020190.45892.75. [DOI] [PubMed] [Google Scholar]
  • 8.Álvarez-Sala L.A., Núñez-Cortés J.M. Evidencias de la eficacia del tratamiento hipocolesterolemiante en la prevención primaria y secundaria de la cardiopatía isquémica. Med Clin (Barc) 2000;114(Supl 2):1–10. [PubMed] [Google Scholar]
  • 9.Abadal L.T., Varas Lorenzo C., Pérez I., Puig T., Balaguer Vintró I. Factores de riesgo y morbi-mortalidad coronaria a los 28 años de seguimiento de una cohorte con baja incidencia de la enfermedad:el estudio de Manresa. Rev Esp Salud Pública. 2004;78:229–241. doi: 10.1590/s1135-57272004000200009. [DOI] [PubMed] [Google Scholar]
  • 10.Wilson P.W., D’Agostino R.B., Levy D., Belenger A.M., Silbershatz H., Kannel W.B. Prediction of coronary hearth disease using risk factor categories. Circulation. 1998;97:1837–1847. doi: 10.1161/01.cir.97.18.1837. [DOI] [PubMed] [Google Scholar]
  • 11.Conroy R.M., Pyöräla K., Fitzgerald A.P., Sans S., Menotti A., De Backer G. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003. doi: 10.1016/s0195-668x(03)00114-3. [DOI] [PubMed] [Google Scholar]
  • 12.Menotti A., Puddu P.E., Lanti M. Comparison of the Framingham risk function-based coronary chart risk function from an Italian population study. Eur Hearth J. 2000;21:365–370. doi: 10.1053/euhj.1999.1864. [DOI] [PubMed] [Google Scholar]
  • 13.Hense H.W., Schulte H., Lowel H., Assman G., Keil U. Framingham risk function overestimates risk of coronary hearth disease in men and women from Germany: results of the MONICA Augsburg and the PROCAM cohorts. Eur Hearth J. 2003;24:937–945. doi: 10.1016/s0195-668x(03)00081-2. [DOI] [PubMed] [Google Scholar]
  • 14.D’Agostino R.B., Grundy S., Sullivan L.M., Wilson P. Validation of the Framingham Coronary Heart Disease Prediction Scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180–187. doi: 10.1001/jama.286.2.180. [DOI] [PubMed] [Google Scholar]
  • 15.Marrugat J., D’Agostino R., Sullivan L., Elosúa R., Wilson P., Ordovás J. An adaptation of the Framingham risk function to southern Europe Mediterranean areas. J Epidemiol Community Health. 2003;57:634–638. doi: 10.1136/jech.57.8.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Maiques Galán A. Valoración del riesgo cardiovascular. ¿Qué tabla utilizar? Aten Primaria. 2003;32:586–589. doi: 10.1016/S0212-6567(03)79337-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Gil-Guillén V., Orozco-Beltrán D., Maiques-Galán A., Aznar-Vicente J., Navarro J., Cea-Calvo L. Concordancia de las escalas REGICOR y SCORE para la identificación del riesgo cardiovascular alto en la población española. Rev Esp Cardiol. 2007;60:1042–1050. doi: 10.1157/13111236. [DOI] [PubMed] [Google Scholar]
  • 18.Buitrago F., Cañón L., Díaz N., Cruces E., Bravo B., Pérez I. Comparación entre la tabla del SCORE y la función Framingham-REGICOR en la estimación del riesgo cardiovascular en una población urbana seguida durante 10 años. Med Clin (Barc) 2006;127:368–373. doi: 10.1157/13092437. [DOI] [PubMed] [Google Scholar]
  • 19.De Backer G., Ambrosioni E., Borch-Johsen K., Brotons C., Cifkova R., Dallongeville J. Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601–1610. doi: 10.1016/s0195-668x(03)00347-6. [DOI] [PubMed] [Google Scholar]
  • 20.Villar F., Maiques A., Brotons C., Torcal J., Banegas J.R., Lorenzo A. Recomendaciones preventivas cardiovasculares en atención primaria. Actualización 2005 del Programa de Actividades Preventivas y de Promoción de la Salud (PAPPS) Aten Primaria. 2005;36(Supl 2):11–26. [Google Scholar]
  • 21.Lamberts H., Wood M., Hofmans-Okkes I.M., editors. The International Classification of Primary Care in the European Community. With a multi-language layer. Oxford University Press; Oxford: 1993. [Google Scholar]
  • 22.The Johns Hopkins ACG® Case-mix System version 7.0-April, 2005 Johns Hopkins Bloomberg School of Public Health. Baltimore, 2005.
  • 23.Weiner J.P., Starfield B.H., Steinwachs D.M., Mumford L.M. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care. 1991;29:452–472. doi: 10.1097/00005650-199105000-00006. [DOI] [PubMed] [Google Scholar]
  • 24.National Cholesterol Education Program-Expert Panel on Detection, Evaluation, and Treatment on High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III final report. Circulation. 2002;106:3143-421. [PubMed]
  • 25.Anónimo . Nordic Collaborating Centre for Drug Statistics Methodology; Oslo: 1991. Guidelines for ATC classification. [Google Scholar]
  • 26.Thompson S.G., Barber J.A. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000;320:1197–1200. doi: 10.1136/bmj.320.7243.1197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Sackett D., Rosenberg W., Gray J., Haynes R.B., Richardson W.S. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312:71–72. doi: 10.1136/bmj.312.7023.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ortega Tallón M.A., Roca Figueres G., Iglesias Rodríguez M., Jurado Serrano J.M. Pacientes hiperfrecuentadores de un centro de atención primaria: características sociodemográficas, clínicas y de utilización de los servicios sanitarios. Aten Primaria. 2004;33:78–85. doi: 10.1016/S0212-6567(04)79355-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Colhoun H.M., Betteridge D.J., Durrington P.N., Neil H.A., Livinstone S.J., Thomason M.J. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696. doi: 10.1016/S0140-6736(04)16895-5. [DOI] [PubMed] [Google Scholar]
  • 30.Brotons C., Royo-Bordonada M.A., Álvarez-Sala L., Armario P., Artigao R.R., Conthe P. Adaptación española de la Guía Europea de Prevención Cardiovascular. Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC) Aten Primaria. 2004;34:427–432. doi: 10.1016/S0212-6567(04)78927-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES